Peptide library

Semax

Semax is a synthetic seven-amino-acid peptide derived from a fragment of the hormone ACTH. What it is, how it has been studied, what regulators said about safety, and where it stands in the US, UK, Australia and sport in November 2026.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

Semax is a synthetic peptide of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro, which FDA staff describe as an analogue of a fragment of the hormone ACTH. Most of its research is in rats and mice. Its human studies are few and mostly small, and FDA staff found insufficient evidence of effectiveness for the three uses they reviewed. It is not FDA-approved.

Key takeaways

  • Semax is H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, a synthetic analogue of the ACTH 4–10 fragment, according to FDA staff.
  • Of 210 PubMed records on Semax (November 2026), 153 involve rats or mice; its human studies are few and mostly small, and none is registered on ClinicalTrials.gov.
  • FDA staff found insufficient evidence of effectiveness for the three uses they evaluated, and insufficient clinical information to characterise its safety.
  • HHS named Semax in a draft, non-binding 2026 compounding policy, which is not an approval; it read the safety record differently from FDA staff, who found too little clinical information to characterise it.
  • It is not named in Australia’s Poisons Standard or on WADA’s 2026 and 2027 Lists, and neither absence means it is approved or permitted.

01Semax at a glance

The short version, dated 18 November 2026. Every line is sourced at the end of the page.

QuestionSemax
What it isA synthetic peptide of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro (C37H51N9O10S, 813.9 g/mol), which FDA staff describe as an analogue of the ACTH 4–10 fragment.
Other names“Semax (heptapeptide)” on FDA’s compounding page; CAS 80714-61-0. An acetate salt also exists.
Evidence tierMostly T3: 153 of 210 PubMed records involve rats or mice. T2 for people: mostly small studies; none we could read describes random assignment, and none is registered on ClinicalTrials.gov.
Human studiesFDA staff found eight references that gave it to people: 33 to 47 healthy adults, 69 adults with medical conditions and 451 children. They found insufficient evidence of effectiveness for the three uses they evaluated.
United StatesNot FDA-approved. In compounding Category 2 from 29 Sep 2023 to 22 Apr 2026, now listed as a nomination withdrawn. Named in HHS’s draft enforcement-discretion policy (30 Oct 2026), which is not binding and not an approval.
United KingdomNo result on the emc medicines database (18 Nov 2026).
AustraliaNot named in the Poisons Standard October 2026 (text searched 18 Nov 2026).
WADANot named on the 2026 or 2027 List; whether class S0 applies is unresolved (see below).

02What is Semax?

Semax is a short synthetic peptide of seven amino acids: methionine, glutamic acid, histidine, phenylalanine, proline, glycine and proline. FDA staff describe it as a synthetic analogue of ACTH 4–10, a fragment of adrenocorticotropic hormone (ACTH). The two sequences differ in their last three amino acids; Semax ends in Pro-Gly-Pro, which is thought to make it more resistant to breakdown by enzymes. Citing a 2013 review, FDA staff write that Semax lacks the hormone’s corticotropic activity, its effect on the adrenal glands.

Most of the research is in animals. Of the 210 PubMed records with Semax in the title or abstract (18 November 2026), 153 involve rats or mice, and 89 are Russian-language articles. FDA staff summarise rodent studies in several areas and call the mechanisms “poorly understood”.

Semax is not the same molecule as Selank, another seven-amino-acid peptide, and their US histories differ: see the Selank guide and Semax and Selank research.

03What human studies of Semax exist, and what did FDA staff conclude?

Few and mostly small studies, none registered on ClinicalTrials.gov (searched 18 November 2026). The table shows who took part, the design and what was measured. It does not report what the authors concluded.

StudyPeopleDesignWhat was measured
Koroleva et al., 199637 people with migraine or facial nerve painOpen-label, no control group (FDA staff)Pain rating scales; nerve-response recordings
Gusev et al., 199730 patients in the acute period of ischaemic stroke; 80 comparison patients on standard careAdded to standard care; the abstract does not describe how patients were assignedClinical rating scales; EEG mapping; evoked potentials
Serdiuk et al., 200727 people with motor neuron diseaseOpen-labelNeedle EMG; disease rating scales; quality of life
Gusev et al., 2018110 adults after ischaemic strokeEarly or late rehabilitation groups, each split into with and without Semax; assignment not described in the abstractBlood BDNF levels; motor strength; Barthel index of everyday activities
Panikratova et al., 202052 healthy participantsSemax, Selank or placeboResting brain connectivity on fMRI, before and twice in the 20 minutes after
Two meeting abstracts (FDA staff)120 children with depression; 331 children with tics or Tourette syndromeSemax alongside other treatments; full studies not availableNot available

Across the eight references FDA staff reviewed, Semax was given to 33 to 47 healthy adults, 69 adults with medical conditions and 451 children. Three were meeting abstracts, and in several Semax was given with other treatments, “making it difficult to determine the contribution of semax to any effects seen”. FDA staff did not consider Russian-language references that lacked English translations, which leaves out both stroke studies above.

FDA staff’s verdict. For the three uses they could evaluate (cerebral ischaemia, migraine and trigeminal neuralgia), FDA staff found “insufficient evidence” of effectiveness: only two references were available, with “insufficient details on the design and conduct of the studies”. How to weigh studies like these: evidence grades.

04What have regulators said about Semax safety?

FDA staff concluded there is “insufficient clinical information to characterize the safety profile” of Semax, and that its use in compounding “may raise safety concerns”. HHS read the same record differently.

FDA. Most of the human references “did not discuss safety”; one reported no adverse events. FAERS, FDA’s adverse-event database, held one report through 3 December 2025: a consumer described eye pain and burning after using a Semax product bought online, and a hospitalisation, with the pain unresolved when reported a year later. FDA staff found no published case reports. They flagged two signals: a meeting abstract describing possible anti-clotting properties, which “raises concern about the risk of bleeding”, and a mouse finding that Semax increased amphetamine-induced dopamine release, a response “typically induced by drugs of abuse”. They found no study of its immunogenicity and are “concerned” about it by the routes nominators proposed; FDA’s compounding page says Semax “may pose risk for immunogenicity for certain routes of administration”.

HHS. HHS’s 2026 policy appendix calls CDER’s safety concerns “mechanistic rather than observed”, saying the human record CDER compiled “covers several hundred subjects with no reported adverse outcome” and that “the bleeding and abuse-potential signals have no clinical counterpart in that record”. FDA staff had noted that most of those references did not discuss safety. More: side effects, documented vs unknown.

05Is Semax an approved medicine? Status by country

United States. Semax is not an FDA-approved drug or a component of one, and Drugs@FDA lists no product containing it (18 November 2026). HHS records that it sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026, that CDER recommended against listing either form, and that the July 2026 advisory committee voted in favour of both. FDA’s compounding page now lists “Semax (heptapeptide)” among nominations withdrawn. HHS then named Semax among six peptides in a policy saying it does not intend to pursue enforcement against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription. The Federal Register notice of 30 October 2026 calls it a draft that “is not binding”. It is not an approval. Background: the July 2026 vote and the HHS policy.

United Kingdom. A search of the emc medicines database for Semax returned no results on 18 November 2026. FDA staff found no Semax monograph in the European, Japanese or International Pharmacopoeia. More: are peptides legal in the UK?

Russia. FDA staff wrote that Semax “is a registered drug in Russia”, citing Russia’s state register of medicines, accessed in December 2025. We could not open that register to confirm it (18 November 2026). Research-grade Semax is not that registered medicine.

Australia. Semax is not named in the Poisons Standard October 2026, and not being named does not make it approved or permitted. See are peptides legal in Australia?

Sport. Semax is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 covers any pharmacological substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”, prohibited at all times. Whether S0 reaches Semax depends on an approval status we could not verify, and anti-doping organisations decide. See peptides and anti-doping.

06What we don’t know about Semax

  • Any effect in people from a registered, placebo-controlled trial. None is on ClinicalTrials.gov, and FDA staff found insufficient evidence for the uses they reviewed.
  • Its safety over months or years, its abuse potential and its bleeding risk. FDA staff found no studies that settle them.
  • Which form the human studies used. FDA staff note the references do not say whether they used the free base or a salt.
  • Its status in Russia. FDA staff report a registration there; we could not open the register to confirm it.
  • What a vial sold as Semax contains. Only that lot’s lab report can show it: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: Semax-related bulk drug substances (FDA evaluation dated 11 May 2026). Advisory committee briefing, 2026 (pp. 7–11, 20–30, 37–44); read 18 Nov 2026. www.fda.gov/media/193348/download
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  3. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026. hhs.gov returned 403 on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest capture of this URL (Appendix B, p. 8). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  4. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 18 Nov 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  5. PubMed: 210 records with Semax in the title or abstract, 153 involving rats or mice and 89 in Russian (searches run 18 Nov 2026). Human studies, abstracts read 18 Nov 2026: Gusev EI et al., Zh Nevrol Psikhiatr Im S S Korsakova 1997 [study of Semax added to standard care in 30 patients with acute ischaemic stroke] (PMID 11517472); Serdiuk AV et al., same journal 2007 [open-label study in 27 patients with motor neuron disease] (PMID 18379501); Gusev EI et al., same journal 2018 [study of 110 patients after ischaemic stroke, with and without Semax] (PMID 29798983); Panikratova YR et al., Dokl Biol Sci 2020 [fMRI study of Semax, Selank and placebo in 52 healthy participants] (PMID 32342318). Koroleva et al. 1996 and the meeting abstracts are cited through FDA’s briefing. pubmed.ncbi.nlm.nih.gov/?term=semax%5Btiab%5D
  6. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027), class S0. International Standard; both PDFs searched 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  7. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, commenced 1 Oct 2026; full text searched 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  8. Database searches run 18 Nov 2026: emc (“semax”: no results); Drugs@FDA via openFDA (“semax”: no records); ClinicalTrials.gov, intervention and term “semax” (no records); PubChem CID 9811102 (formula, weight, CAS 80714-61-0). Registry and database queries. pubchem.ncbi.nlm.nih.gov/compound/9811102

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What is Semax?

A synthetic peptide of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro, that FDA staff describe as an analogue of a fragment of the hormone ACTH. Most of its research is in rats and mice.

Is Semax FDA-approved?

No. HHS named it in a draft 2026 enforcement-discretion policy for licensed pharmacies and physicians who compound it, which is not binding and is not an approval.

Has Semax been tested in humans?

In a few, mostly small studies: FDA staff counted eight references, three of them meeting abstracts, and none is registered on ClinicalTrials.gov. FDA staff found insufficient evidence of effectiveness for the three uses they evaluated.

Is Semax the same as Selank?

No. Both are seven-amino-acid peptides, but Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Selank was not on FDA’s July 2026 committee agenda and is not in HHS’s policy.

Is Semax prohibited in sport?

It is not named on WADA’s 2026 or 2027 List. Class S0 covers pharmacological substances with no current government approval for human therapeutic use, and anti-doping organisations decide how it applies.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page